Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/52834
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bongetti E.K. | - |
dc.contributor.author | Wolfe R. | - |
dc.contributor.author | Wetmore J.B. | - |
dc.contributor.author | Murray A.M. | - |
dc.contributor.author | Woods R.L. | - |
dc.contributor.author | Fravel M.A. | - |
dc.contributor.author | Nelson M. | - |
dc.contributor.author | Stocks N. | - |
dc.contributor.author | Orchard S.G. | - |
dc.contributor.author | Polkinghorne K. | - |
dc.date.accessioned | 2025-01-06T02:50:46Z | - |
dc.date.available | 2025-01-06T02:50:46Z | - |
dc.date.copyright | 2024 | - |
dc.date.issued | 2024-11-13 | en |
dc.identifier.citation | Journal of the American Society of Nephrology. Conference: Kidney Week 2024. San Diego, CA United States. 35(pp 415), 2024. Date of Publication: 2024. | - |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/52834 | - |
dc.description.abstract | Background: A recalibrated version of CKD-EPI2009, without a race coefficient, was released in 2021 (CKD-EPI2021). This updated equation, implemented in the US, can result in the reclassification of chronic kidney disease (CKD) stage in a significant proportion of individuals. The aim of this study was to investigate the clinical impact of transitioning from the 2009 CKD-EPI (CKD-EPI2009) to the 2021 CKD-EPI (CKD-EPI2021) estimated glomerular filtration rate (eGFR) equation in generally healthy older Australians. Method(s): This was a prospective cohort study using data from 16,244 Australian community-dwelling adults aged >=70 years, in the ASPirin in Reducing events in the Elderly (ASPREE) study cohort. Baseline characteristics and long-term health outcomes were compared in participants who were reclassified to a different chronic kidney disease (CKD) stage with CKD-EPI2021 versus those with unchanged classification. Result(s): With CKD-EPI2021, baseline eGFR increased by a median of 3.8 mL/min/ 1.73m2 (interquartile range [IQR] 3.3, 4.4) resulting in the reclassification of 3,106 (20%) participants to a less advanced CKD stage and the reduction in the prevalence of CKD from 17% to 12%. Over a median follow-up period of 6.5 years (IQR 5.4, 7.9), there was no difference in disability-free survival (HR: 0.94, 95%CI:0.84-1.05), mortality (HR: 0.90, 95%CI:0.78-1.03), major cardiac events (HR: 0.94, 95%CI:0.79-1.13), or hospitalisations for heart failure (HR: 1.00, 95%CI:0.67-1.49) in reclassified, versus nonreclassified, participants. Conclusion(s): Implementing CKD-EPI2021 would raise eGFR by a median of nearly 4 ml/min/1.73m2, substantially reducing the proportion of older Australian adults classified as having CKD with no difference in long-term health outcomes among reclassified people. Transitioning to using the CKD-EPI2021 may result in a significant reduction in nephrology referrals in generally healthy, older adults. | - |
dc.relation.ispartof | Journal of the American Society of Nephrology | - |
dc.subject.mesh | cardiovascular disease | - |
dc.subject.mesh | chronic kidney failure | - |
dc.title | Impact of the CKD-EPI 2021 equation on the classification of CKD in older Australian adults. | - |
dc.type | Conference Abstract | - |
dc.identifier.affiliation | Nephrology | - |
dc.description.conferencename | Kidney Week 2024 | - |
dc.description.conferencelocation | San Diego, CA, United States | - |
dc.type.studyortrial | Observational study (cohort, case-control, cross sectional, or survey) | - |
local.date.conferencestart | 2024-10-23 | - |
dc.identifier.institution | (Bongetti, Polkinghorne) Monash University, Department of Medicine, Clayton, VIC, Australia | - |
dc.identifier.institution | (Bongetti, Polkinghorne) Department of Nephrology, Monash Health, Melbourne, VIC, Australia | - |
dc.identifier.institution | (Wolfe, Woods, Orchard) Monash University, School of Public Health and Preventative Medicine, Melbourne, VIC, Australia | - |
dc.identifier.institution | (Wetmore) Division of Nephrology, Hennepin Healthcare, Minneapolis, MN, United States | - |
dc.identifier.institution | (Murray) Berman Center for Outcomes and Clinical Research and Department of Medicine, Hennepin Healthcare Research Institute, Department of Medicine, Geriatrics Division, Hennepin Healthcare, Minneapolis, MN, United States | - |
dc.identifier.institution | (Fravel) Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Minneapolis, MN, United States | - |
dc.identifier.institution | (Nelson) University of Tasmania, Menzies Institute for Medical Research, Hobart, TAS, Australia | - |
dc.identifier.institution | (Stocks) Adelaide Medical School, Discipline of General Practice, Adelaide, SA, Australia | - |
local.date.conferenceend | 2024-10-27 | - |
dc.identifier.affiliationmh | (Bongetti, Polkinghorne) Department of Nephrology, Monash Health, Melbourne, VIC, Australia | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairetype | Conference Abstract | - |
crisitem.author.dept | Nephrology | - |
Appears in Collections: | Conferences |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.